Proactive case-finding and risk-stratification in people at risk of chronic liver disease in Greater Manchester: a cost-effectiveness analysis

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background

We urgently need innovative strategies to combat a growing epidemic of chronic liver disease (CLD). ID-LIVER was a collaborative project aiming to improve detection of reversible-stage CLD in a region with high prevalence of critical risk factors.

Objective

To determine the cost-effectiveness of ways to identify people with significant CLD, including proactive case-finding in the community (supplementing reactive referrals from primary care) and/or risk-stratification (using FIB-4 or ID-LIVER-ML -- a novel machine-learning risk-stratification tool).

Design

State-transition decision-analytic model estimating lifetime healthcare costs (2023/24 GBP) and quality-adjusted life-years (QALYs) associated with six alternative strategies for case-finding and risk-stratification. We simulated cohorts of people with alcohol-related liver disease (ARLD) and metabolic dysfunction-associated steatotic liver disease (MASLD). We populated the model with data collected in ID-LIVER, supplemented by parameters from literature and routine data-sources. We estimated incremental cost-effectiveness and performed deterministic and probabilistic sensitivity analyses.

Results

Any case-identification strategy costing ≤3,300 GBP per person with significant CLD identified would meet English cost-effectiveness thresholds (20,000 GBP/QALY). In our decision-set, the cheapest strategy is to use FIB-4 in the reactive-only population. ID-LIVER-ML generates more population health at reasonable cost (10,490 GBP/QALY gained). Introducing proactive case-finding generates further health benefits, costing 12,952 GBP/QALY gained. Using ID-LIVER-ML in the proactive-and-reactive population has the highest probability of maximising cost-effectiveness, when valuing QALYs at 20,000 GBP.

Conclusion

Smart methods of case-finding and risk-stratification identify people with significant CLD in the community, and are likely to represent good value for money in England.

Article activity feed